The $15bn ‘viral’ AI start-up changing how American doctors treat patients

Recent reporting from the Financial Times details a $15 billion viral artificial intelligence start-up that is actively changing how American doctors treat patients. According to coverage from Nurse.org and other outlets, new findings published in JAMA reveal that nurse practitioners and physician assistants are outquerying doctors on OpenEvidence. Additional coverage by eMarketer notes that the search patterns of physicians using these AI tools are providing the pharmaceutical industry with novel methods for delivering more relevant advertising. The Financial Times highlights the massive valuation and viral adoption of the platform within the medical community, signaling a major shift in clinical workflows across the United States. Coverage emphasizes several distinct angles across multiple publications, including the Financial Times, Nurse.org, eMarketer, Wolters Kluwer, and STAT.

Wolters Kluwer focuses on the transition from traditional content to clinical intelligence, emphasizing the delivery of trusted evidence directly where care happens. Meanwhile, STAT reports that the JAMA paper regarding OpenEvidence leaves open questions that have not yet been fully answered. The intersection of clinical search behavior, pharmaceutical marketing, and advanced medical intelligence forms the core narrative tracked by these various outlets, highlighting both rapid adoption and ongoing scrutiny. Context provided by the coverage indicates that medical professionals are increasingly turning to specialized search tools like OpenEvidence rather than relying solely on conventional clinical references or traditional search engines. The active engagement of nurse practitioners and physician assistants alongside doctors demonstrates a broad multi-disciplinary reliance on artificial intelligence platforms at the point of care.

Furthermore, the commercial implications highlighted by eMarketer show that these clinician search patterns are intersecting with pharmaceutical advertising strategies, creating entirely new touchpoints for relevant drug delivery and medical marketing based on real-time professional queries. As coverage continues to unfold, readers and industry observers must monitor several factors based strictly on the current reporting. The extent to which the open questions surrounding the JAMA paper will be addressed remains to be seen in future research and reporting. Observers will also track how the $15 billion start-up maintains its viral trajectory among American doctors, nurse practitioners, and physician assistants, alongside the evolving relationship between clinical AI search platforms and pharmaceutical advertising practices. Current reporting does not yet specify exact timelines for upcoming studies or regulatory actions related to these technologies.